Abstract
Introduction
Vitamin D is a fat soluble vitamin that is involved in bone metabolism and calcium homeostasis (1) . It has been emerging over recent years that vitamin D may have a role in disorders outside the skeletal system including immune disorders, diabetes, hypertension, cardiovascular disease, infectious diseases and cancer (2) (3) (4) . Vitamin D deficiency is very prevalent worldwide, as people adopt sedentary indoor lifestyles and use sunscreen and protective clothing to reduce skin cancer risk (5) . Despite our sunny climate, vitamin D deficiency is also common in Australia. The AusDiab Study reported vitamin D deficiency (vitamin D <50 nmol/L) in 50% of women and 31% of men living at latitudes >35 degrees south -which includes Melbourne, the location of the current study (6) . Low vitamin D levels have been found in type 2 diabetes mellitus (T2DM) and correlate with obesity, pancreatic beta cell dysfunction and insulin resistance (IR) and risk of developing T2DM (7) (8) (9) (10) . Supplementation of vitamin D has been shown to improve IR (11) and prevent T2DM (9) .
Polycystic ovary syndrome (PCOS) is a common disorder that affects 9-21% of reproductiveaged women (12), depending on the population studied and the diagnostic criteria applied.
PCOS diagnosis is based on menstrual disturbance (oligo or amenorrhoea), clinical or biochemical hyperandrogenism and polycystic ovaries on ultrasound (13) . IR plays a central pathophysiological role in the majority of women with PCOS (14) and underpins significant metabolic complications in PCOS including dyslipidaemia, dysglycaemia and hyperandrogenism (15) . IR in PCOS is both independent of and exacerbated by obesity (16) .
Approximately 60% of Australian women with PCOS are overweight or obese and women with PCOS may also have a relatively greater central adiposity distribution compared to controls with equivalent BMI (16 (22) . It has been suggested that vitamin D may have a protective effect on some cardiovascular risk factors (23) .
To this end, we measured adiposity, IR (gold standard measures), lipid profile and blood pressure in lean and overweight women with PCOS and without PCOS to further explore relationships between vitamin D, metabolic and cardiovascular risk factors in PCOS. The current study adds to existing literature with the inclusion of both women with PCOS and controls, including lean and overweight subjects and the use of clamp studies and detailed body composition measures. We hypothesized that obese women will have lower vitamin D compared to lean women and women with PCOS will have lower vitamin D levels compared to women without PCOS. In addition, we hypothesized that vitamin D will be further lowered by presence of cardiovascular risk factors.
Methods and methods

Subjects
Women were recruited from community advertisements (16) . This vitamin D study is part of a PCOS study investigating insulin resistance in PCOS (16) . 76 women were eligible and had completed 3 months run-in phase as previously described (16) . The women were categorised according to PCOS status and BMI. Women were allocated into two BMI categories (lean and overweight) based on the threshold BMI of 27kg.m -2 , as an a priori decision, as this is the inflexion point in the relationship between BMI and IR (16) . We analysed baseline data from 76 women (n=22 lean women and n=20 overweight women with PCOS and n=19 lean and n=15 overweight control women without PCOS).
As previously described, diagnosis of PCOS was undertaken by expert endocrinologists The Southern Health Research Advisory and Ethics Committee approved the study and all participants gave written informed consent.
Study Design
At screening (3 months prior to baseline), standard diet and lifestyle advice were delivered [Heart Foundation of Australia recommendations (www.heartfoundation.org.au)] as previously described (25) . Medications affecting end-points including insulin sensitisers, anti-androgens and hormonal contraceptives were ceased for 3 months. Data were collected following this 3 month run-in phase and was collected in the follicular phase of the menstrual cycle wherever feasible.
Anthropometric Measurements
Participants were weighed lightly clothed without shoes (Tanita TBF310, Tokyo, Japan)
followed by height measurements (Stadiometer Holtain, Wales, UK) for the calculation of
. Waist circumference (WC) was measured at the umbilicus by an experienced operator.
Body Composition and Adipose Tissue Distribution
Fat mass, abdominal fat mass and fat-free mass (FFM) were measured by dual-energy x-ray absorptiometry (DEXA) as described elsewhere (25) . Single-slice Computer Tomography (CT) images were acquired at the level of L4-L5 intervertebral disc space and abdominal visceral fat (AVF) and abdominal subcutaneous fat cross-sectional areas (centimeters squared) were calculated as previously described (25) .
Hyperinsulinaemic euglycaemic Clamp
IR was measured using the hyperinsulinaemic euglycaemic clamp technique as previously described (25, 26) . Fasting venous blood samples were collected, centrifuged and stored for assessment of glucose, insulin, vitamin D, total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides as previously described (25 
Metabolic syndrome
Metabolic syndrome was determined using the World Health Organization (WHO) criteria which requires the presence of IR in addition to at least two other criteria (28) . However, we did not have any information regarding urine albumin excretion, which is one of the additional criteria.
Statistics
All data were analysed using STATA software version 11.0 (StataCorp, TX). Data were assessed for normality and log transformed where appropriate and analysed using univariate analysis of variance (ANOVA). Post hoc analysis was conducted adjusting for multiple comparisons using the appropriate method (tukey) to adjust for possible type 1 errors.
Continuous data are presented as mean ± SD or median (interquartile range) as appropriate.
Correlation of vitamin D with IR, adiposity and cardiovascular risk factors was assessed 9 using Pearson or Spearman rank correlation where appropriate. Linear regression was used for assessment of factors associated with plasma vitamin D levels. Statistical significance was set at  level of p < 0.05.
Results
Results are presented for 76 subjects with samples available for analysis including vitamin D.
22 lean women and 20 overweight women with PCOS and 19 lean and 15 overweight control women without PCOS were eligible at screening, completed the 3 month run-in phase with a steady diet, were compliant with withdrawal of relevant medications affecting glucose metabolism and completed data collection.
PCOS vs. non-PCOS women: cardiometabolic status and vitamin D levels
All baseline metabolic and clinical characteristics are presented in Tables 1 and 2 . The overweight women with PCOS were younger than controls (29.8±5.5 years vs 35.1±4.1, p=0.004). There were no significant differences within the lean and obese groups with regard to blood pressure or lipid profile (Table 2) . nmol/L respectively, p=0.01) and this persisted after adjustment for BMI and abdominal visceral fat (p=0.01). Vitamin D levels were similar between lean groups (p=0.97) ( Table 2) .
Vitamin D and obesity
10
The lean and overweight experimental groups had similar adiposity within groups as determined by BMI and visceral abdominal fat content determined by CT (Table 2) 
Vitamin D and insulin resistance
IR was not different between the lean PCOS and overweight controls as previously reported (16) . As expected, IR was greatest in the overweight PCOS cohort and lowest in the lean PCOS cohort (Table 2) . Vitamin D levels were positively associated with GIR (r=0.31, p=0.01). Vitamin D was associated with IR (GIR) on univariate regression (β coefficient 1.5, 95% CI 0.4 -2.6, p=0.01), but was not associated with IR on multivariate regression when adjusted for PCOS status, age and % body fat. Both PCOS and % body fat were associated with IR in the multivariable regression model (β coefficient -66.3, 95% CI -104.5 --28.2, p=0.001 and β coefficient -3.7, 95% CI -5.6 --1.8, p<0.001) ( Table 3) . To adjust for seasonal effects, the month of the year when clamp data were collected was included in the multivariable regression model, with no significant effect on results. There was a significant interaction between PCOS and % body fat for the outcome of IR (p=0.003).
Further analysis by PCOS status revealed that vitamin D was associated with IR, independent of % body fat in the PCOS group (β coefficient 2.1, 95% CI 0.2 -4.0, p=0.03). Vitamin D was not associated with IR in the non-PCOS group (Table 4) .
Vitamin D and CVD risk factors
There was a relationship between vitamin D and triglycerides after adjustment for age (p=0.01); however, this relationship was no longer significant after further adjustment for abdominal visceral fat (p=0.29). There was also a moderate correlation between vitamin D and high density lipoprotein (HDL) cholesterol before (r=0.38, p=0.001) and after adjustment for age and % body fat (p=0.001 and p=0.03 respectively). However, this relationship was no longer significant after further adjustment for abdominal visceral adiposity (p=0.23). There was no correlation with vitamin D and total cholesterol or LDL cholesterol levels. There was no correlation between vitamin D and systolic or diastolic blood pressure.
Vitamin D and metabolic syndrome
Ten of the 42 PCOS participants (23.8%) and three of the 33 control participants (9.1%) 
Discussion
In the present study, we report that despite similar adiposity, vitamin D levels were lower in overweight women with PCOS compared with overweight controls. We also showed using 
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